Bristol-Myers Squibb Co.

NYSE:BMY   12:58:26 PM EDT
56.54
-1.70 (-2.92%)
Products, Regulatory

Bristol Myers Squibb Provides Update On Phase 2 Study Of Deucravacitinib In Patients With Moderate To Severe Ulcerative Colitis

Published: 10/07/2021 11:49 GMT
Bristol-Myers Squibb Co. (BMY) - Bristol Myers Squibb Provides Update on Phase 2 Study of Deucravacitinib in Patients With Moderate to Severe Ulcerative Colitis.
Bristol-myers Squibb Co - Lattice-uc Proof of Concept Study Did Not Meet Primary Nor Secondary Endpoints.
Bristol-myers Squibb Co - Continues to Expect Greater Than $4 Billion Non-risk Adjusted Revenue Target for Deucravacitinib in 2029.
Bristol-myers - Safety Profile of Deucravacitinib Consistent With Other Trials & No New Safety Signals Reported.